PRAMEF18

Across TCGA pan-cancer cohorts, PRAMEF18 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of PRAMEF18’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where PRAMEF18 RNA is repressed in tumor relative to normal tissue. In most cancer types PRAMEF18 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

BRCA are the cancer types where PRAMEF18 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRAMEF18 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	−0.006	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

PRAMEF18–BRCA

Open the BRCA breakdown →